Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia
Authors:
- 30 April 2013
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 97 (5) , 573-580
Abstract
Alemtuzumab, a humanized anti-CD52, IgG1 monoclonal antibody, is used to reduce graft-versus- host disease (GVHD) and aid engraftment after allogeneic haemopoietic stem cell transplant (HSCT). Its associated low incidence of GVHD makes it an attractive alternative to anti-thymocyte globulin (ATG) in transplant conditioning regimen for severe aplastic anaemia (SAA). We have reviewed the use of alemtuzumab-based conditioning regimen for HSCT in SAA and show that it results in sustained haematological engraftment, a very low incidence of chronic GVHD without an increase in viral infections. Intriguingly, alemtuzumab appears to induce tolerance post-HSCT with the findings of stable mixed T cell chimerism with full donor myeloid chimerism and the absence of chronic GVHD, and which persist on withdrawal of post-graft immunosuppression. Finally, its low toxicity profile may permit future application of HSCT to older patients with SAA who fail to respond to immunosuppressive therapy.Keywords
This publication has 41 references indexed in Scilit:
- Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemiaBlood, 2011
- Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemiaBlood, 2011
- Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-Identical Siblings for Severe Aplastic Anemia in Patients Over 40 Years of AgeTransplantation and Cellular Therapy, 2010
- Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donorsHaematologica, 2010
- Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working partyHaematologica, 2010
- Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimenHaematologica, 2009
- Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumabHaematologica, 2009
- Thyroid function following hematopoietic cell transplantation in children: 30 years' experienceBlood, 2009
- Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemiaBlood, 2007
- Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimensBlood, 2007